Literature DB >> 27745544

Pediatric Differentiated Thyroid Cancer: When to Perform Conservative and Radical Surgery.

Claudio Spinelli1, Leonardo Rossi, Jessica Piscioneri, Silvia Strambi, Alessandro Antonelli, Andrea Ferrari, Maura Massimino, Paolo Miccoli.   

Abstract

Thyroid tumors affect all age groups, including children and adolescents. Malignant cancer of the thyroid is a relatively uncommon disease in pediatric age. In the recent decades the incidence of paediatric differentiated thyroid carcinoma (DTC) has increased. DTC in paediatric age is rare and has an excellent prognosis. Compared to adult counterpart, DTC in childhood presents some different features as follows: larger volume at the diagnosis, more frequent multicentricity (both mono- and bilateral), earlier local involvement of soft tissue of the neck, earlier lymph node involvement, distant metastases 3-4 times more frequent (most often in the lungs and almost always functional) and more common post-operatory recurrence; nevertheless, the prognosis of DTC in childhood is better and the survival greater than in adult. Because of unusual association between aggressive presentation and good prognosis, the choice about the surgical treatment to perform in DTC is debatable, especially between conservative and radical approach in TNM stage I pediatric patients. To date, total thyroidectomy is the operation most often performed in children with DTC, although recently conservative surgery has been performed in solitary unifocal nodule without evidence distant metastases. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Adolescent surgery; pediatric age; pediatric surgery; thyroid cancer.

Mesh:

Year:  2016        PMID: 27745544     DOI: 10.2174/1573396312666161014092023

Source DB:  PubMed          Journal:  Curr Pediatr Rev        ISSN: 1573-3963


  6 in total

1.  Cervical Lymph Node Metastases of Papillary Thyroid Carcinoma, in the Central and Lateral Compartments, in Children and Adolescents: Predictive Factors.

Authors:  C Spinelli; F Tognetti; S Strambi; R Morganti; M Massimino; P Collini
Journal:  World J Surg       Date:  2018-08       Impact factor: 3.352

2.  Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma.

Authors:  Changjiao Yan; Meiling Huang; Xin Li; Ting Wang; Rui Ling
Journal:  Endocr Connect       Date:  2019-07       Impact factor: 3.335

3.  Thyroid cancer in children: A multicenter international study highlighting clinical features and surgical outcomes of primary and secondary tumors.

Authors:  Cristina Martucci; Alessandro Crocoli; Maria Debora De Pasquale; Claudio Spinelli; Silvia Strambi; Paolo Brazzarola; Eleonora Morelli; Jessica Cassiani; Juliana Mancera; Juan Pablo Luengas; Pablo Lobos; Daniel Liberto; Estefanìa Astori; Sabine Sarnacki; Vincent Couloigner; François Simon; Cassandre Lambert; Simone de Campos Vieira Abib; Onivaldo Cervantes; Eliana Caran; Diana Delgado Lindman; Matthew O Jones; Rajeev Shukla; Paul D Losty; Alessandro Inserra
Journal:  Front Pediatr       Date:  2022-07-22       Impact factor: 3.569

4.  Outcome and complications after surgery for thyroid carcinoma in pediatric age-an evaluation of practice.

Authors:  Ahmed Elgendy; Emad M Shehata; Sherif M Shehata
Journal:  World J Surg Oncol       Date:  2022-09-14       Impact factor: 3.253

5.  Increased trend of thyroid cancer in childhood over the last 30 years in EU countries: a call for the pediatric surgeon.

Authors:  Claudio Spinelli; Marco Ghionzoli; Chiara Oreglio; Beatrice Sanna; Luigi De Napoli; Riccardo Morganti; Alessandro Antonelli; Antonino Morabito; Paolo Miccoli
Journal:  Eur J Pediatr       Date:  2022-08-31       Impact factor: 3.860

6.  Paediatric differentiated thyroid carcinoma: a UK National Clinical Practice Consensus Guideline.

Authors:  Sasha R Howard; Sarah Freeston; Barney Harrison; Louise Izatt; Sonali Natu; Kate Newbold; Sabine Pomplun; Helen A Spoudeas; Sophie Wilne; Tom R Kurzawinski; Mark N Gaze
Journal:  Endocr Relat Cancer       Date:  2022-09-07       Impact factor: 5.900

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.